- Home
- SRZN vs UNCY Comparison
SRZN vs UNCY Comparison
Compare SRZN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- UNCY
- Stock Information
- Founded
- SRZN 2015
- UNCY 2016
- Country
- SRZN United States
- UNCY United States
- Employees
- SRZN N/A
- UNCY N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- UNCY Health Care
- Exchange
- SRZN Nasdaq
- UNCY Nasdaq
- Market Cap
- SRZN 82.8M
- UNCY 71.8M
- IPO Year
- SRZN N/A
- UNCY 2021
- Fundamental
- Price
- SRZN $8.48
- UNCY $0.60
- Analyst Decision
- SRZN Strong Buy
- UNCY Strong Buy
- Analyst Count
- SRZN 2
- UNCY 3
- Target Price
- SRZN $38.50
- UNCY $5.50
- AVG Volume (30 Days)
- SRZN 10.0K
- UNCY 510.7K
- Earning Date
- SRZN 05-20-2025
- UNCY 05-16-2025
- Dividend Yield
- SRZN N/A
- UNCY N/A
- EPS Growth
- SRZN N/A
- UNCY N/A
- EPS
- SRZN N/A
- UNCY N/A
- Revenue
- SRZN $10,655,000.00
- UNCY N/A
- Revenue This Year
- SRZN N/A
- UNCY N/A
- Revenue Next Year
- SRZN N/A
- UNCY $1,502.84
- P/E Ratio
- SRZN N/A
- UNCY N/A
- Revenue Growth
- SRZN N/A
- UNCY N/A
- 52 Week Low
- SRZN $6.00
- UNCY $0.20
- 52 Week High
- SRZN $18.17
- UNCY $1.16
- Technical
- Relative Strength Index (RSI)
- SRZN 45.80
- UNCY 54.73
- Support Level
- SRZN $8.49
- UNCY $0.59
- Resistance Level
- SRZN $11.56
- UNCY $0.66
- Average True Range (ATR)
- SRZN 0.69
- UNCY 0.03
- MACD
- SRZN -0.05
- UNCY -0.00
- Stochastic Oscillator
- SRZN 37.13
- UNCY 57.75
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.